Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects

Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

James B. Bussel, Gregory Cheng, Mansoor N. Saleh et al. · New England Journal of Medicine · 2007 · 805 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

James B. Bussel, Drew Provan, Tahir Shamsi et al. · The Lancet · 2009 · 539 citations

Medicine, Hematology, Pharmacotherapy +10

Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C

John G. McHutchison, Geoffrey Dusheiko, Mitchell L. Shiffman et al. · New England Journal of Medicine · 2007 · 450 citations

Medicine, Pharmacology, Pharmacotherapy +17

Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission

Kelem Kassahun, Paul G. Pearson, Wei Tang et al. · Chemical Research in Toxicology · 2000 · 307 citations

Medicine, Pharmacology, Toxicology +14

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist

J.M. Jenkins, Daphne Williams, Yanli Deng et al. · Blood · 2007 · 299 citations

Medicine, Pharmacology, Pharmacotherapy +5